Led by $635m acquisition of Capsule Technologies, North America’s medical devices industry saw a rise of 34.83% in cross border deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 60 cross border deals worth $2.25bn were announced for the region during Q1 2021, against the last four-quarter average of 44.50 deals.
Of all the deal types, venture financing saw most activity in Q1 2021 with 31 deals, representing a 51.7% share for the region.
In second place was M&A with 23 deals, followed by private equity deals with six transactions, respectively capturing a 38.3% and 10% share of the overall cross border deal activity for the quarter.
In terms of value of cross border deals, M&A was the leading category in North America’s medical devices industry with $1.16bn, while venture financing and private equity deals totalled $715.46m and $369.67m, respectively.
North America medical devices industry cross border deals in Q1 2021: Top deals
The top five medical devices cross border deals accounted for a 53% share of the overall value during Q1 2021.
The combined value of the top five cross border deals stood at $1.19bn, against the overall value of $2.25bn recorded for the quarter.
The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:
1) Koninklijke Philips’ $635m acquisition of Capsule Technologies
2) The $240m acquisition of Alydia Health by Organon
3) Fidelity Management & Research and T Rowe Price Associates’ $115m private equity deal with Kardium
4) The $110m acquisition deal with 7D Surgical by SeaSpine
5) Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans’ venture financing with Hyperfine Research for $90m.